复旦我江 FUDAN-ZHANGJIANG 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) (股票號碼：1349) " 僅供歲別 年報 2021 目錄 頁碼 | --- | |--------------------| | | | 公司資料 | | 五年財務摘要 | | 主席報告 | | 管理層的討論及分析 | | 董事會報告 | | 監事會報告 | | 審核委員會報告 | | 薪酬委員會報告 | | 提名委員會報告 | | 戰略委員會報告 | | 獨立非執行董事報告 | | | 2 4 6 20 33 63 66 69 71 73 75 企業管治報告 77 | --- | --- | |-------|----------------------------| | | | | | 董事、監事及高級管理層簡介 | | | 環境、社會及管治報告 | | | 獨立核數師報告 | | | 合併財務報表 | | • | 合併資產負債表 | | • | ...

上海復旦張江生物醫藥股份有限公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * (Stock Code: 1349) (a joint stock company incorporated in the People's Republic of China with limited liability) INTERIM REPORT 2021 中期報 告 INTERIM REPORT For the six months ended 30 June 2021 * For identification purpose only 上海復旦張江生物醫藥股份有限公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * （股票號碼：1349） （於中華人民共和國註冊成立的股份有限公司） 截至二零二一年六月三十日止六個 月 中期報 告 * 僅供識別 公司主要財務指標 一、公司主要會計數據和財務指標 （一）五年財務摘要 業績 | --- | --- | --- | --- | --- | - ...

Financial Performance - Total revenue for the year ended December 31, 2020, was RMB 833.8 million, a decrease of 19% from RMB 1,029.3 million in 2019[4] - Profit before tax for 2020 was RMB 176.7 million, down 28.2% from RMB 246.3 million in 2019[4] - The net profit attributable to shareholders for 2020 was RMB 164.7 million, a decrease of 27.6% compared to RMB 227.4 million in 2019[4] - The company reported a basic and diluted earnings per share of RMB 0.1663 for 2020, down from RMB 0.2463 in 2019[4] - The company's main business revenue for 2020 was approximately RMB 832,467,000, a decrease of 19% compared to RMB 1,028,955,000 in 2019[60] - Sales revenue from medical and diagnostic products was RMB 820,810,000, down 17.68% from RMB 997,065,000 in 2019, with major products contributing 36%, 53%, and 9% to total revenue[61] - The company confirmed technology transfer income of approximately RMB 11,500,000 in 2020, down from RMB 29,900,000 in 2019[62] - The company’s net profit margin for 2020 was 20%, down from 21% in 2019, primarily due to decreased sales revenue and increased R&D expenses[77] - The company achieved a revenue of approximately 834 million RMB in 2020, representing a year-on-year decline of 19%[103] Assets and Liabilities - The company's total assets increased to RMB 2,500.7 million in 2020, up 60% from RMB 1,564.8 million in 2019[6] - The total liabilities for 2020 were RMB 492.2 million, a decrease from RMB 631.7 million in 2019[6] Research and Development - The company emphasizes a long-term value-oriented R&D strategy, focusing on projects that meet clinical needs and demonstrate unique therapeutic effects[9] - The R&D strategy is concentrated on antibody-drug conjugates (ADCs) for tumors, photodynamic drugs for skin diseases and cervical precancerous lesions, and small molecule targeted drugs for autoimmune diseases and tumors[12] - Research and development expenses for the year 2020 amounted to RMB 139,268,000, a 9% increase from RMB 127,822,000 in 2019[68] - Total research and development investment for 2020 was RMB 154,973,000, representing a 19% increase compared to the previous year[71] - The proportion of research and development investment to operating revenue was 18.59% in 2020[71] Product Development and Innovation - The company aims to become an innovator and leader in the biopharmaceutical industry, focusing on addressing clinical treatment gaps[9] - The company is focusing on drug development in oncology, dermatology, and autoimmune diseases, while exploring new research directions in molecular targeting and immunotherapy[102] - The company has developed PEGylated doxorubicin liposome, which shows lower cardiac toxicity and improved tumor targeting compared to traditional formulations[125] - The company is actively involved in the research and development of liposomal formulations, which have shown promising results in reducing side effects associated with traditional chemotherapy[121] - The company has established a nanotechnology platform to develop lipid-based formulations, with its drug 裡葆多® launched in 2009, aiming to enhance industrialization capabilities[142] Market and Sales Strategy - The ongoing COVID-19 pandemic significantly impacted hospital operations and sales strategies, yet the company maintained normal operations[9] - The company is developing a new sales model for Fumida®, integrating direct distribution with hospitals and pharmaceutical companies[45] - The company is exploring new sales models utilizing its WeChat platform for academic promotion and interaction between doctors and patients[46] - The recovery of drug distribution and hospital patient visits has begun as the domestic pandemic is under control, but patient numbers remain significantly below normal levels[103] Corporate Governance and Shareholder Information - The board proposed a final dividend of RMB 0.05 per share for the year ending December 31, 2020, totaling approximately RMB 52,150,000[163] - The company has implemented a stable and proactive profit distribution policy since 2015, ensuring a cash dividend distribution of no less than 10% of the distributable profit each year[160] - The company maintains a diverse shareholder base, including both domestic and foreign investors[196] - The company has purchased liability insurance for directors and senior management to cover their responsibilities and risks associated with daily operations[189] Future Outlook and Strategic Initiatives - The company is positioned for long-term growth driven by factors such as aging population and increasing health awareness, despite short-term challenges from the pandemic[57] - The company plans to enhance gross profit levels while maintaining strict cost control under the current industry structure[65] - The company aims to leverage the advantages of combining vascular inhibitors with PD-1 in ADC drug development for lung and liver cancer treatments[22] - The company plans to utilize the remaining fundraising by December 31, 2023, in accordance with its development strategy[100]

上海復旦張江生物醫藥股份有限公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * (Stock Code: 1349) (a joint stock company incorporated in the People's Republic of China with limited liability) INTERIM REPORT 2020 中期報 告 INTERIM REPORT For the six months ended 30 June 2020 上海復旦張江生物醫藥股份有限公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * （股票號碼：1349） （於中華人民共和國註冊成立的股份有限公司） 中期報 告 截至二零二零年六月三十日止六個 月 * 僅供識別 * For identification purpose only 公司主要財務指標 一、公司主要會計數據和財務指標 （一）五年財務摘要 業績 | --- | --- | --- | --- | --- | - ...

复旦我江 FUDAN-ZHANGJIANG 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) (股票號碼：1349) 年 報 2019 * 僅供識別 公司資料 2 五年財務摘要 4 主席報告 6 管理層的討論及分析 17 董事會報告 28 監事會報告 46 審核委員會報告 47 薪酬委員會報告 49 提名委員會報告 51 企業管治報告 52 環境、社會及管治報告 78 董事、監事及高級管理層簡介 98 獨立核數師報告 103 • 合併資產負債表 108 • 公司資產負債表 110 • 合併利潤表 112 • 公司利潤表 114 • 合併現金流量表 115 • 公司現金流量表 117 • 合併股東權益變動表 119 • 公司股東權益變動表 120 • 財務報表備註 121 • 財務報表補充資料 241 目 錄 公司資料 周忠惠 林耀堅 執行董事 王海波（主席） 蘇勇 趙大君 非執行董事 沈波 余曉陽 獨立非執行董事 許青 楊春寶 監事 周曦（主席 ...

上海復旦張江生物醫藥股份有限公司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * (Stock Code: 1349) (a joint stock company incorporated in the People's Republic of China with limited liability) INTERIM REPORT 2019 中期報告 INTERIM REPORT For the six months ended 30 June 2019 上海復旦張江生物醫藥股份有限公司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. * （股票號碼：1349） （於中華人民共和國註冊成立的股份有限公司） 截至二零一九年六月三十日止六個月 中期報告 * 僅供識別 * For identification purpose only 五年財務摘要 業績 未經醫核 | --- | --- | --- | --- | --- | --- | |---------------------- ...

* (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 1349) Annual Report Annual Report 2018 年報 For identification purpose only * (於中華人民共和國註冊成立的股份有限公司) (股票號碼：1349) 2018 2018 年 報 * * * 僅供識別 目 錄 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 公司資料 公 | | | | | | 2 | | | 五年財務摘要 | | | | | | 4 | | | 主席報告 | | | | | ...